Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07249788
PHASE4
Resmiterom Efficacy & Safety in Patients With MASH
Sponsor: Nabiqasim Industries (Pvt) Ltd
View on ClinicalTrials.gov
Summary
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
Official title: Clinical Evaluation of Safety and Efficacy of Resmiterom in Patients With MASH (Metabolic Dysfunction-Associated Steato-Hepatitis) A Prospective, Open-label, Interventional Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
165
Start Date
2025-10-17
Completion Date
2026-12-31
Last Updated
2025-12-03
Healthy Volunteers
No
Interventions
DRUG
Resmetirom
1st FDA approved MASH therapy
Locations (1)
Liver transplant center, Holy family hospital
Rawalpindi, Punjab Province, Pakistan